Asia Pacific Glucagon Like Peptide 1 Agonists Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

GLP-1 agonists are a class of injectable and oral therapies that mimic the incretin hormone to regulate blood glucose and appetite, with leading molecules including semaglutide, liraglutide, dulaglutide and exenatide. The Asia-Pacific market represents a meaningful share of global GLP-1 revenues, anchored by large patient pools in China, Japan, South Korea, India and Australia. Diabetes prevalence in the region exceeds 200 million adults, while obesity rates are climbing rapidly in urban populations, creating sustained baseline demand for these therapies.

• •Market valued at approximately USD 4.2 billion in 2025 with a ~6.0% CAGR outlook
• •Tier-1 indications are type 2 diabetes, with obesity and weight management expanding fastest
• •Key molecules in use include semaglutide, liraglutide, dulaglutide and exenatide

Rising diabetes and obesity prevalence, combined with growing physician familiarity and patient awareness of GLP-1 therapies, is the principal demand engine. Regulatory approvals of new indications such as chronic weight management and cardiovascular risk reduction are widening the eligible patient base. Greater inclusion of GLP-1 agonists in national reimbursement schemes and the launch of oral formulations are improving access and adherence across the region.

• •Surging type 2 diabetes and obesity cases, particularly in China, India and Southeast Asia
• •Label expansions into cardiovascular and chronic kidney disease indications
• •Inclusion in national reimbursement lists in markets such as Japan and Australia

By molecule, semaglutide dominates revenue, with liraglutide and dulaglutide holding established positions and newer entrants gaining traction. By indication, diabetes remains the largest segment while obesity and weight management is the fastest-growing. Geographically, China and Japan are the largest revenue contributors, followed by Australia, South Korea and India, where uptake is accelerating as supply and affordability improve.

• •Semaglutide leads by molecule; injectable formulations still outweigh oral in unit volume
• •China and Japan together account for the majority of regional revenue
• •Australia is among the fastest-growing developed markets, with projections approaching USD 1.9 billion by the mid-2030s

What are the recent trends and outlook?

Oral GLP-1 formulations and next-generation dual and triple incretin agonists are expected to redefine competitive positioning through the late 2020s. Supply expansion, including new manufacturing capacity from both multinational and local producers, is gradually easing shortages that constrained growth in earlier years. Over the forecast period, the market is likely to benefit from broader reimbursement for obesity indications, deeper penetration in emerging Asian economies, and growing real-world evidence supporting cardiovascular and renal benefits.

• •Oral and dual/triple incretin agonists are the next wave of launches
• •Manufacturing capacity additions across the region are easing supply constraints
• •Reimbursement expansion into obesity is a key upside catalyst through 2030